Business Wire (Free subscription) | 10/11/2008
LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company announces that it has now commenced clinical trials for an extended warfarin sensitivity
Medical News Today (Free subscription) | 05/11/2008
Osmetech plc (LSE:OMH), the international molecular diagnostics company announces the launch of a genetic test for CYP450 2C9 drug metabolism. CYP450 2C9, or CYP2C9, is an important member of the Cytochrome P450 family of enzymes responsible for detoxifying potentially hazardous chemicals, such as drugs, that are "foreign" to the body. The CYP2C9 gene is important in its involvement in the metabolism...
Business Wire (Free subscription) | 31/10/2008
LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company announces that Dr. Charles S. Eby, M.D., Associate Professor at the Washington University in
Business Wire (Free subscription) | 22/09/2008
PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc (‘Osmetech’) (LSE:OMH), the international molecular diagnostics business, today
Business Wire (Free subscription) | 12/09/2008
PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc, a molecular diagnostics company, (LSE:OMH) (proposed NASDAQ Global Market Symbol: OSMH) today announced that it has filed a registration
Business Wire (Free subscription) | 12/08/2008
LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the fast developing international molecular diagnostics business announces that Daryl Jay Faulkner, 59, will join the Company as
Red Orbit (Free subscription) | 31/07/2008
Speaking at the American Association for Clinical Chemistry (AACC) 2008 Conference and Exhibition in Washington, DC, James White, Chief Executive, Osmetech plc (LSE:OMH), confirmed that following receipt of its 510(k) clearance last week from the US Food & Drug Administration ('FDA'), the Company has now commenced shipments of its second generation eSensor(R) XT-8 molecular diagnostics platform and...
Medical News Today (Free subscription) | 23/07/2008
Osmetech plc announced that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its eSensor Warfarin Sensitivity Test to be used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug, warfarin. The Company also announces that the FDA clearance includes its second generation eSensor XT-8 molecular diagnostics...
Business Wire (Free subscription) | 07/01/2008
LONDON--(BUSINESS WIRE)--Osmetech plc ('Osmetech' or the 'Company') (LSE:OMH), the fast developing international molecular diagnostics business announces that it has submitted its
